Biofarma Pharmaceuticals, which has an annual production capacity of 76 million boxes, has reserved 55 million boxes for SOLID PRODUCTION and 9 million boxes for LIQUID PRODUCTION, and the remaining part is determined as SEMI SOLID, SOFT GELATIN CAPSULE, HORMONE production. In addition, we are ready to increase its machinery park and production capacity by making new investments in line with the increasing product range and contract manufacturing demands from our customers.
In our production facility, which works with the principle of continuous development and lean production, daily and weekly KPIs (Performance Criteria) of all machines and lines are closely followed- we make low-cost and high-quality products accessible by improving machines and lines with the relevant data.
All products come in the following forms as semi-finished and finished products in the production and packaging areas, which are two main sections.
Biofarma products are produced in accordance with PICS GMP international standards and exported to more than 30 countries, including EU countries, Middle East, Africa, Far East, CIS and other countries.
Biofarma, which carries out contract manufacturing for the leading generic manufacturers in Europe, also supplies hormone products to 12 different European countries.
Biofarma has 183 product licenses in the export countries. We a’m to increase the number of these licenses to 311 in 3 years with new projects.
Biofarma is overseen by national and international health authorities such as the UK MHRA, the Libyan Ministry of Health and the State Administration of Ukraine.